Ocumetics Technology Corp (TSE:OTC)
:OTC
Want to see TSE:OTC full AI Analyst Report?
Top Page
Ocumetics Technology Corp
(OTC)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.57
▲(4.36% Upside)
Action:ReiteratedDate:04/25/26
The score is held down primarily by weak financial performance (no revenue, persistent losses and cash burn, negative equity with rising debt). Technical indicators are moderately supportive in the short to medium term, but longer-term trend signals remain mixed, and valuation support is limited due to ongoing losses and no dividend data.
Positive Factors
Specialized ophthalmic product focus
A focused product strategy targeting accommodative intraocular lenses concentrates R&D and commercial efforts on a clear clinical need. If the technology proves safe and effective, this specialization supports durable differentiation, targeted go-to-market execution, and clearer regulatory/commercial pathways over months.
Negative Factors
No revenue / negative gross profit
The absence of revenue and persistent negative gross profit confirm a pre-commercial stance with ongoing product delivery costs but no sales. Over the medium term this means the company must bridge to commercialization via financing, and cannot yet prove demand, unit economics, or sustainable margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized ophthalmic product focus
A focused product strategy targeting accommodative intraocular lenses concentrates R&D and commercial efforts on a clear clinical need. If the technology proves safe and effective, this specialization supports durable differentiation, targeted go-to-market execution, and clearer regulatory/commercial pathways over months.
Read all positive factors
Ocumetics Technology Corp (OTC) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$30.98M
Dividend YieldN/A
Average Volume (3M)77.99K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth-67.18%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,414,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ocumetics Technology Corp Business Overview & Revenue Model
Company Description
Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the...
How the Company Makes Money
null...
Ocumetics Technology Corp Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Jul 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -134.30K | -117.62K | -102.21K | -96.18K |
| EBITDA | -3.87M | -2.29M | -3.50M | -2.09M | -3.42M |
| Net Income | -5.37M | -3.02M | -3.64M | -2.22M | -598.19K |
Balance Sheet | |||||
| Total Assets | 1.90M | 2.32M | 1.04M | 1.37M | 825.25K |
| Cash, Cash Equivalents and Short-Term Investments | 464.04K | 1.57M | 235.83K | 602.09K | 83.90K |
| Total Debt | 5.30M | 3.95M | 321.64K | 292.34K | 0.00 |
| Total Liabilities | 5.85M | 4.26M | 945.33K | 536.45K | 1.10M |
| Stockholders Equity | -3.94M | -1.94M | 91.10K | 837.40K | -270.50K |
Cash Flow | |||||
| Free Cash Flow | -3.49M | -2.51M | -2.19M | -1.69M | -213.63K |
| Operating Cash Flow | -3.37M | -2.43M | -2.05M | -1.62M | -89.13K |
| Investing Cash Flow | 1.25M | -1.46M | -142.17K | -66.82K | -214.92K |
| Financing Cash Flow | 2.38M | 3.85M | 1.82M | 444.35K | 387.11K |
Ocumetics Technology Corp Technical Analysis
Positive
0.55
Price Trends
0.46
Positive
0.55
Positive
0.73
Negative
Market Momentum
0.04
Negative
64.60
Neutral
56.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OTC, the sentiment is Positive. The current price of 0.55 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.46, and below the 200-day MA of 0.73, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 64.60 is Neutral, neither overbought nor oversold. The STOCH value of 56.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:OTC.
Ocumetics Technology Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$53.86M | 95.68 | 3.31% | ― | -9.04% | -80.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$41.62M | -5.70 | -258.64% | ― | 176.72% | 30.90% | |
50 Neutral | C$19.70M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
48 Neutral | C$30.98M | -13.69 | ― | ― | ― | -67.18% | |
46 Neutral | C$21.47M | -29.60 | -31.12% | ― | 9.71% | -118.02% |
* Healthcare Sector Average
TSE:OTC
Ocumetics Technology Corp
0.60
0.32
110.53%
TSE:ASG
Aurora Spine
0.28
-0.07
-21.43%
TSE:COV
Covalon Technologies
1.90
-0.21
-9.95%
TSE:PINK
Perimeter Medical Imaging AI
0.33
-0.06
-15.58%
TSE:VPT
VentriPoint Diagnostics
0.10
-0.04
-25.93%
TSE:CNVI
Conavi Medical
0.40
0.01
2.56%
Ocumetics Technology Corp Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Ocumetics Advances First-in-Human Lens Trials After Productive ASCRS Meetings
Positive
Apr 14, 2026
Ocumetics Technology Corp., a Canadian developer of next-generation intraocular lenses and other vision correction technologies, is conducting first-in-human feasibility studies on an accommodating lens designed to fit within the eye’s natur...
Business Operations and StrategyProduct-Related Announcements
Ocumetics to Court Strategic Partners as First-In-Human Lens Data Debuts at ASCRS
Positive
Apr 1, 2026
Ocumetics Technology Corp., a Canadian ophthalmic technology developer, is advancing a first-in-human feasibility study for its accommodating intraocular lens, which is intended to leverage the eye’s natural muscles to provide seamless visio...
Business Operations and StrategyProduct-Related Announcements
Ocumetics Unveils Streamlined Breakthrough Design for Next-Generation Intraocular Lens
Positive
Mar 31, 2026
Ocumetics Technology Corp. announced major design breakthroughs in its accommodating intraocular lens platform, the Ocumetics Lens, achieved through collaboration with engineering and manufacturing partners in Germany and Mexico. The company has s...
Business Operations and StrategyProduct-Related Announcements
Ocumetics Grants Stock Options to IR Advisor as It Advances Novel Intraocular Lens
Positive
Mar 14, 2026
Ocumetics Technology Corp., a Canadian ophthalmic RD company developing advanced intraocular lenses and other vision-enhancing technologies, is currently running a first-in-human early feasibility study on a lens designed to sit in the eye’s...
Business Operations and StrategyProduct-Related Announcements
Ocumetics forms scientific advisory committee to steer late-stage development of accommodating intraocular lens
Positive
Feb 26, 2026
Ocumetics Technology Corp., a developer of next-generation ophthalmic devices, is advancing a novel intraocular lens designed to sit in the eye’s natural lens compartment and use the eye’s own muscle activity to provide clear vision fr...
Business Operations and StrategyExecutive/Board Changes
Ocumetics Adds Capital Markets Veteran to Board as It Advances Novel Intraocular Lens
Positive
Feb 24, 2026
Ocumetics Technology Corp., a Canadian developer of advanced intraocular lenses and other ophthalmic innovations, is in a first-in-human early feasibility study for a lens designed to sit in the eye’s natural lens compartment. The device is ...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Extends Debenture Forbearance and Closes $1.02 Million LIFE Financing
Positive
Feb 11, 2026
Ocumetics Technology Corp. has secured a forbearance agreement with holders of up to $4 million in secured convertible debentures issued in 2024, under which lenders will refrain from enforcing repayment or realizing on security until June 19, 202...
Business Operations and StrategyProduct-Related Announcements
Ocumetics De-Risks Accommodating Lens Platform With Strong First-in-Human Results
Positive
Feb 3, 2026
Ocumetics Technology Corp. reported positive three-month postoperative results from the first group of patients in its first-in-human clinical study of its accommodating intraocular lens, with data meeting or exceeding internal benchmarks for safe...
Business Operations and StrategyPrivate Placements and Financing
Ocumetics Seeks Debenture Forbearance and Warrant Incentive to Extend $4 Million Financing
Neutral
Jan 31, 2026
Ocumetics Technology Corp. has proposed a forbearance agreement with holders of its up to $4 million secured convertible debentures issued in 2024, under which debentureholders would agree not to demand repayment or enforce their security until Ju...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.